Vectura Group
From Wikipedia, the free encyclopedia
 |
|
| Type | Public (LSE: VEC) |
|---|---|
| Industry | Pharmaceuticals |
| Founded | 1997 |
| Headquarters | Chippenham, UK |
| Key people | Jack Cashman, Chairman Christopher Blackwell, (CEO) |
| Revenue | £25.2 million (2008) |
| Operating income | £(25.1) million (2008) |
| Net income | £(19.2) million (2008) |
| Website | www.vectura.com |
Vectura Group plc is a leading British-based pharmaceuticals business. It is based in Chippenham and is a former constituent of the FTSE 250 Index.
Contents |
History[edit]
Vectura was formed in 1997 with venture finance backing. In 1999 it acquired Co-ordinated Drug Development and the Centre for Drug Formulation Studies. In 2002 it acquired inhaler technology and an associated engineering team from Cambridge Consultants.[1]
In 2004 it was listed on the Alternative Investment Market.[1] In 2007 it acquired Innovata plc, a developer of pulmonary products,[1][2] and then moved on the full list of the London Stock Exchange.[1]
Operations[edit]
The Group specialises in inhalation technology and currently has two main focuses:
- Respiratory: inhaled products for asthma and COPD
- Neurology: products for Parkinson's Disease and migraine
References[edit]
- ^ a b c d Vectura Group:History
- ^ Vectura buys Innovata Guardian, 17 November 2006
External links[edit]
- Official site
- Vectura boosted by deal with GSK worth over $30 million upfront plus royalties The Pharma Letter,6th August, 2010
